Clinical Trials
4
Active:0
Completed:1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay
Not yet recruiting
- Conditions
- T-Cell Lymphoproliferative Disorder
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06876571
- Locations
- 🇺🇸
Invivoscribe, Inc., San Diego, California, United States
🇩🇪LabPMM GmbH, Hallbergmoos, Germany
🇯🇵LabPMM GK, Kawasaki-shi, Kanagawa, Japan
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
Recruiting
- Conditions
- Hematologic Diseases
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT06222164
- Locations
- 🇺🇸
LabPMM, San Diego, California, United States
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay
Completed
- Conditions
- B-Cell Lymphoproliferative Disorder
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06112301
- Locations
- 🇺🇸
Invivoscribe, Inc., San Diego, California, United States
🇩🇪LabPMM GmbH, Hallbergmoos, Germany
🇯🇵LabPMM GK, Kawasaki-shi, Kanagawa, Japan
The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines
- Conditions
- SARS-CoV-2
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04391400
News
No news found